Why Is AstraZeneca Plc Up Today?

AstraZeneca Plc (LSE:AZN) shares rose 0.98% to 14,162.0p today, supported by continued attention on its latest quarterly update and a deep pipeline of late-stage medicines.

In the first nine months of 2026, total Revenue rose 8% to $46,881m and Core Earnings Per Share rose 14% to $8.00, with oncology again the largest growth driver. The company reconfirmed its full-year guidance.

Today's gain therefore sits against a backdrop of solid fundamentals and a defensive healthcare sector. The sections below review the latest results, therapy areas, pipeline, Dividend and risks.

About AstraZeneca Plc

AstraZeneca Plc is a global, science-led biopharmaceutical company that discovers, develops and sells prescription medicines. Its three main therapy areas are Oncology, BioPharmaceuticals and Rare Disease.

BioPharmaceuticals covers cardiovascular, renal and metabolism, respiratory and immunology, and infectious disease medicines. Pascal Soriot is Chief Executive.

The shares trade on the London Stock Exchange under LSE:AZN and are among the largest companies in the UK market by value.

Key Reasons Behind Today's Uptick

Today's 0.98% rise appears to reflect steady Demand for large, defensive healthcare shares and continued confidence in the company's earnings visibility. No new announcement is required to explain a move of this size.

AstraZeneca's recent figures have shown growth that is broad across regions, and management says it is on track to deliver its 2030 ambition. Pipeline progress, with 12 positive Phase III programme readouts so far this year, has also kept attention on the company.

Investors in LSE:AZN are also watching how the Business offsets the loss of exclusivity on older products with newer medicines.

9M and Q3 2026 Financial Performance

For the nine months to 30 September 2026, total revenue was $46,881m, up 8% (7% at constant exchange rates). Product sales were $43,962m, up 7%. Reported EPS rose 10% to $5.62, and Core EPS rose 14% to $8.00. Core operating profit was $16,365m, up 14%.

In the third quarter, total revenue was $16,209m, up 7%. Reported EPS rose 23% to $2.02 and Core EPS rose 17% to $2.79, or 19% at constant exchange rates. Core operating profit was $5,855m, up 17%, with a Core Operating Margin of 36%.

Cash flow from operations in the nine months was $10,890m.

The faster growth in Core EPS than in revenue shows operating leverage, with the Core operating margin reaching 36% in the quarter. Reported EPS grew more slowly over nine months than Core EPS because reported figures include restructuring costs and Amortisation of acquired intangible assets.

Full-Year 2026 Guidance

AstraZeneca reconfirmed guidance for 2026 at constant exchange rates. It expects total revenue to increase by a mid-to-high single-digit percentage and Core EPS to increase by a low double-digit percentage, with a Core tax rate of 18% to 22%.

At September 2026 average exchange rates, total revenue would benefit by a low single-digit percentage, unchanged from the previous update.

Oncology Leads Growth

Oncology revenue was $21,889m in the nine months, 47% of the total, up 18% (16% at constant exchange rates). Third-quarter oncology revenue rose 17%.

Key medicines include Tagrisso at $5,862m, up 8%, Imfinzi at $5,538m, up 27%, and Enhertu at $2,688m, up 33%. These products show how newer cancer therapies are broadening the revenue base.

Rare Disease revenue was $7,544m, up 12%, representing 16% of total revenue.

BioPharmaceuticals and Loss of Exclusivity

BioPharmaceuticals revenue was $16,731m, 36% of the total, and declined 2% (5% at constant exchange rates). The decline reflects loss of exclusivity for Farxiga and Brilinta and volume-based procurement in China.

Farxiga revenue was $5,683m, down 15% at constant exchange rates. Managing this transition is one of the central tasks for the business.

Because the decline is concentrated in a few mature products, the growth of newer medicines is what determines whether group revenue can keep rising at a mid-to-high single-digit pace. Oncology and Rare Disease together accounted for 63% of nine-month revenue, which gives a large and growing base to offset those pressures.

Regional Performance

US revenue was $19,789m in the nine months, up 7%. Europe was $10,528m, up 15% (10% at constant exchange rates), with third-quarter growth of 12% at constant exchange rates.

Emerging Markets revenue was $12,515m, up 7% (3% at constant exchange rates). Within that, China was $5,430m, up 3%, and Emerging Markets excluding China was $7,085m, up 11%.

Pipeline and Regulatory Progress

AstraZeneca has had 12 positive Phase III programme readouts this year, including DESTINY-Lung04, DeLLphi-305, MONO-OLA1, SAFFRON, SANOVO, CLARITY-Gastric01, VOLGA and tozorakimab trials in COPD. There have been 47 approvals in major regions since the fourth-quarter 2025 results, and four new medicines received first approvals: Etcamah, Baxfendy, Klygefa and Amlypave.

There have also been setbacks. SERENA-4 did not meet its primary endpoint, the eVOLVE-Lung02 and AWAKE programmes were discontinued, and CARDIO-TTRansform for Wainua did not meet its primary endpoint.

Pending US priority reviews include Imfinzi in muscle-invasive bladder cancer, tozorakimab in COPD, efzimfotase alfa in HPP and Ultomiris in paediatric HSCT-TMA. Management has said the 2027 readouts have potential of more than $20bn.

The breadth of the pipeline across cancer, respiratory, rare disease and metabolic conditions reduces dependence on any single trial result. Even so, individual readouts can move sentiment, which is why the mixture of successes and setbacks this year matters to investors.

Dividend and Capital Allocation

AstraZeneca intends to increase its annual dividend declared for 2026 to $3.30 per share. Dividends paid in the first nine months totalled $4,955m.

Capital allocation priorities are investing in the business and pipeline, maintaining investment-grade Credit status, pursuing value-enhancing business development and supporting a progressive dividend. Net Debt was $25,833m at 30 September 2026.

Capital expenditure on property, plant and equipment and software was $2,284m in the nine months, and is expected to rise by a low-teens percentage for the full year, driven by Manufacturing expansion projects.

The dividend increase signals confidence in cash generation, although the level of manufacturing Investment and business development activity will also influence how much flexibility the group has in future years.

Cost Programme

The Reshaping for Sustainable Growth programme could cost up to $2.0bn in one-time charges and deliver $1.5bn in annualised pre-tax savings, which are being reinvested mainly in the pipeline.

Programmes of this kind can improve margins over time, but they also carry execution risk and near-term charges. The balance between cost control and continued investment in R&D is a key part of the group's operating model.

Sector and Economic Exposure

As a global pharmaceutical group, AstraZeneca is exposed to healthcare pricing policy, particularly in the US and China, as well as currency movements, Patent expiries and regulatory decisions.

Currency translation is a further factor, since the group reports in US dollars while selling in many currencies. Healthcare shares are often viewed as defensive because demand for medicines is less cyclical than many other sectors, although they remain sensitive to policy and clinical trial outcomes.

Risks to Consider

Risks include clinical trial failures, delays to regulatory approvals, price controls, loss of exclusivity on key products and competition from other drug developers.

Higher capital spending and the cost of restructuring also affect cash flow. Net debt of $25,833m is another figure to monitor alongside the dividend commitment. Investors should weigh these against the strength of the pipeline and the company's revenue growth.

Conclusion

AstraZeneca Plc (LSE:AZN) shares rose 0.98% to 14,162.0p today, against a backdrop of 8% nine-month revenue growth, 14% Core EPS growth and reconfirmed full-year guidance.

For investors following LSE:AZN, the main areas to watch are oncology momentum, the impact of loss of exclusivity on Farxiga, upcoming regulatory decisions and the 2027 pipeline readouts. Full-year and fourth-quarter 2026 results are scheduled for 9 February 2027.